Search Results - "Pestchanker, Claudia"
-
1
Severe febrile neutropenia associated with satralizumab in an Argentinian neuromyelitis optica spectrum disorder patient
Published in Multiple sclerosis (01-01-2023)“…Background: Recently, satralizumab (interleukin-6 receptor blocker) was approved for seropositive neuromyelitis optica spectrum disorder (NMOSD) patients. In…”
Get full text
Journal Article -
2
Achieving no evidence of disease activity-3 in highly active multiple sclerosis patients treated with cladribine and monoclonal antibodies
Published in Multiple sclerosis journal - experimental, translational and clinical (01-01-2023)“…Background We aimed to determine the proportion of highly active multiple sclerosis patients under high-efficacy therapies (HETs) achieve no evidence of…”
Get full text
Journal Article -
3
The real‐world applicability of the 2023 international myelin oligodendrocyte glycoprotein antibody‐associated disease criteria in a Latin American cohort
Published in European journal of neurology (01-12-2024)“…Background and Purpose The diagnostic criteria for myelin oligodendrocyte glycoprotein antibody (MOG‐IgG)‐associated disease (MOGAD) were published in 2023. We…”
Get full text
Journal Article -
4
Occurrence of area postrema syndrome during follow-up: phenotype and influence over NMOSD activity in LATAM in real-world settings
Published in Journal of neurology (01-07-2024)“…Introduction We aimed to assess the frequency, duration, and severity of area postrema syndrome (APS) during follow-up in neuromyelitis optica spectrum…”
Get full text
Journal Article -
5
Frequency of new asymptomatic MRI lesions during attacks and follow-up of patients with NMOSD in a real-world setting
Published in Multiple sclerosis (01-09-2023)“…Background: We aimed to assess the frequency of new asymptomatic lesions on brain and spinal imaging (magnetic resonance imaging (MRI)) and their association…”
Get full text
Journal Article -
6
Incidence of SARS-CoV-2 infection in patients with multiple sclerosis who received SARS-CoV-2 vaccines and are under treatment with high-efficacy therapies in Argentina
Published in Neurological sciences (01-02-2024)“…We aimed to evaluate the incidence of SARS-CoV-2 breakthrough infection of SARS-CoV-2 vaccines in people with MS (PwMS) on high-efficacy disease-modifying…”
Get full text
Journal Article -
7
Evaluation of the use of high-efficacy treatments (HETs) in patients with relapsing-remitting multiple sclerosis in Argentina
Published in Multiple sclerosis and related disorders (01-11-2023)“…•There are limited data regarding the use of high-efficacy treatments in LATAM.•One third of those patients received HETs as the first treatment, in second…”
Get full text
Journal Article -
8
Evaluation of the times of disability progression and related factors in patients with primary progressive multiple sclerosis from Argentina
Published in Multiple sclerosis and related disorders (01-02-2022)“…Background PPMS (primary progressive multiple sclerosis) patients represent less than 10% of MS patients in Argentina, men and women were similarly affected…”
Get full text
Journal Article